wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3
Q41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
P2860
Q41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ca41b6a0ef9ea66630e2fb071d7c88e734ee9e5e
P2860
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].